Clinical trials Brief October 5, 2026, 10:03 AM ET

Genmab registers Phase 3 trial of Rina-S in ovarian cancer

The study plans to enroll 602 participants and is expected to start in November 2026. It compares Rina-S alone or in combination with an approved standard of care treatment against the same available standard of care therapy by itself, or no treatment.

Primary source

ClinicalTrials.gov registry record, October 5, 2026

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer

Read the source: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer clinicaltrials.gov

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation